Improving Heart Pump Outcomes Using Advanced Data Analysis
Part of Heart & circulation clinical trials.
This study examines detailed data from patients who received an Impella 5.5 heart pump to treat cardiogenic shock—a life-threatening condition where the heart cannot pump enough blood. Researchers use advanced computer analysis to understand what helps patients recover best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were treated for cardiogenic shock (severe heart failure) and received an Impella 5.5 pump
- You are 18 years old or older
- Your hospital has detailed electronic records and pump data from your treatment available
- Your medical records are complete, including procedure notes and basic demographic information
- The pump was used specifically for cardiogenic shock, not for other heart procedures like protected angioplasty
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people in the intensive care unit who are using a heart pump called Impella. It will collect information about how well the heart pumps blood during treatment to help doctors learn more.
This trial tests whether switching to a more powerful heart pump (Impella 5.5) within 24 hours of a heart attack helps people whose hearts are still struggling despite a standard pump. It may be an option for patients who had a heart attack, received an Impella CP pump, but still need strong medication to keep blood flowing.
This study reviews how well people tolerated the Impella heart pump during cardiogenic shock and what complications occurred. It looks at past cases from 2010 to 2022 to help doctors understand the safety of this device.
This trial tests a new heart pump (Impella device) for people who have a severe heart attack and go into shock (very low blood pressure). It aims to see if the pump can help the heart recover better than standard care.
This trial tests whether using a temporary heart pump plus close monitoring improves recovery in people with severe heart failure after a heart attack, compared to standard care.
This study compares two support devices (Impella vs. IABP) for people with cardiogenic shock who are already on ECMO. It looks at how well the left side of the heart recovers when one of these devices is added.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.